Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)

@article{Mohty2015SinusoidalOS,
  title={Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)},
  author={M. Mohty and F. Malard and M. Abecassis and E. Aerts and A. Alaskar and M. Aljurf and M. Arat and P. Bader and F. Baron and A. Bazarbachi and D. Blaise and F. Ciceri and S. Corbacioglu and J. Dalle and R. Duarte and T. Fukuda and A. Huynh and T. Masszi and M. Michallet and A. Nagler and M. N{\'i}Chonghaile and T. Pagluica and C. Peters and F. Petersen and P. Richardson and T. Ruutu and B. Savani and E. Wallhult and I. Yakoub-Agha and E. Carreras},
  journal={Bone Marrow Transplantation},
  year={2015},
  volume={50},
  pages={781 - 789}
}
Sinusoidal obstruction syndrome or veno-occlusive disease (SOS/VOD) is a potentially life-threatening complication of hematopoietic SCT (HSCT). This review aims to highlight, on behalf of the European Society for Blood and Marrow Transplantation, the current knowledge on SOS/VOD pathophysiology, risk factors, diagnosis and treatments. Our perspectives on SOS/VOD are (i) to accurately identify its risk factors; (ii) to define new criteria for its diagnosis; (iii) to search for SOS/VOD biomarkers… Expand

Paper Mentions

Interventional Clinical Trial
Sinusoidal obstruction syndrome (SOS) or hepatic veno-occlusive disease (VOD) is a serious complication that occurs, most often occurring in patients undergoing hematopoietic stem cell… Expand
ConditionsHematopoietic Stem Cell Transplant (HSCT), Sinusoidal Obstruction Syndrome (SOS)
InterventionDrug
Interventional Clinical Trial
ELASTOVOD is a prospective multicenter study, involving several centers of Onco-haematology in Italy. Investigators perform hepatic elastographic measurements (with Transient… Expand
ConditionsSinusoidal Obstruction Syndrome, Stem Cell Transplant Complications, Veno Occlusive Disease, Hepatic
InterventionDevice
Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group
TLDR
An international consensus guideline for the treatment and prevention of SOS/VOD in adult patients is proposed on behalf of an international expert group. Expand
Identification and Management: Sinusoidal obstruction syndrome/veno‐occlusive disease related to hematopoietic stem cell transplantation
TLDR
This article describes the syndrome, risk factors, signs and symptoms, and appropriate supportive care and treatment of Sinusoidal obstruction syndrome and offers some practical tips for detecting SOS/VOD and providing patient care. Expand
Manifestations and management of veno-occlusive disease/sinusoidal obstruction syndrome in the era of contemporary therapies.
TLDR
An extensive review of the literature on monoclonal antibodies reveals that only a few have been associated with an increased risk for VOD/SOS, and bevacizumab appears to have a protective effect against the development of VOD /SOS. Expand
Defibrotide for the treatment of severe hepatic veno-occlusive disease/sinusoidal obstruction syndrome: evidence for clinical benefit
TLDR
Clinical data show that defibrotide reduces the mortality associated with VOD/SOS, and this agent may therefore help fill an important and unmet therapeutic need. Expand
Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation
TLDR
A new definition for diagnosis, and a severity-grading system for SOS/VOD in adult patients, are proposed on behalf of the European Society for Blood and Marrow Transplantation. Expand
Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation
TLDR
New diagnostic and severity criteria for SOS/VOD in children on behalf of the European Society for Blood and Marrow Transplantation are proposed. Expand
Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
  • S. Corbacioglu, E. Jabbour, M. Mohty
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2019
TLDR
The latest studies reporting VOD/SOS risk factors support previously published data, although the importance of patient-related factors, such as acute kidney injury, increased international normalized ratio, female sex (in children), and platelet refractoriness, is given greater emphasis in the recent data. Expand
Veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic stem cell transplantation: Middle East/North Africa regional consensus on prevention, diagnosis and management
TLDR
A group of regional experts have developed a consensus statement on the diagnosis, prevention and management of VOD/SOS in the Middle East and North Africa region to help in the management of HSCT patients in the region. Expand
Imaging in Hepatic Veno-occlusive Disease/Sinusoidal Obstruction Syndrome.
TLDR
Evidence on the use of imaging in the management of veno-occlusive disease/sinusoidal obstruction syndrome and how imaging biomarkers can contribute to earlier diagnosis/treatment is discussed. Expand
Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
  • Adrien Picod, Agnès Bonnin, +17 authors M. Mohty
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2018
TLDR
In the experience defibrotide prophylaxis is associated with a low incidence of SOS/VOD after allogeneic HSCT in a high-risk adult population with an acceptable safety profile. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 76 REFERENCES
BCSH/BSBMT guideline: diagnosis and management of veno‐occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation
TLDR
It is suggested that the role of plasminogen activator inhibitor 1 levels remains an area for further research but that these levels should not form part of the routine diagnostic work‐up for VOD (SOS) at present. Expand
How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation
TLDR
A review of transplantation teams' policies regarding preventive measures in high‐risk patients, strict daily control of weight and fluid balance during HCT, homogeneous diagnostic criteria, appropriate complementary studies for a correct differential diagnosis and measures to prevent and manage hepatorenal syndrome based on the author's personal experience. Expand
Veno‐occlusive disease of the liver after hemopoietic cell transplantation
TLDR
The clinical syndrome of veno‐occlusive disease after hemopoietic cell transplantation is characterised by jaundice, painful liver enlargement, and fluid retention with weight gain, but 20–25% of patients could die of VOD. Expand
Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions.
TLDR
VOD is a potentially lifethreatening complication after hematopoietic stem cell transplantation (HSCT) that affects both adult and pediatric populations alike, with a higher incidence in the allogeneic setting. Expand
Drug safety evaluation of defibrotide
TLDR
Current clinical findings on DF are reviewed, primarily in terms of safety for use in treatment and prophylaxis of VOD, and relevant safety data for its use in other diseases are reviewed. Expand
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.
TLDR
The evolution of MOF in the setting of VOD after SCT can be considered a reliable indication of severity and a predictor of poor outcome, and the methods used to evaluate severity are discussed. Expand
Treatment of Severe Veno-Occlusive Disease With Defibrotide: Compassionate Use Results in Response Without Significant Toxicity in a High-Risk Population
TLDR
Nineteen patients who developed severe VOD after SCT were treated with DF on a compassionate-use basis and the observed response rate, survival to day +100, and absence of significant DF treatment-associated toxicity are compelling and warrant further evaluation. Expand
Incidence and Outcome of Hepatic Veno-Occlusive Disease After Blood or Marrow Transplantation: A Prospective Cohort Study of the European Group for Blood and Marrow Transplantation
TLDR
The incidence of hepatic veno-occlusive disease after blood or marrow transplantation (BMT) is lower than that reported in smaller studies from single centers, main risk factors have a major impact on incidence of VOD, and the use of prophylactic unfractionated heparin does not seem to reduce the incidence. Expand
A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
TLDR
This study showed that younger age, type of VOD prophylaxis, and busulphan-based conditioning regimens are independent risk factors for VOD. Expand
Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.
TLDR
DF in children resulted in higher CR compared with HC; use of DF was associated with improved outcome in less sick pts, and the 2 groups were balanced regarding stratification variables. Expand
...
1
2
3
4
5
...